Where do Corvus Pharmaceuticals's ratios come from?

Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Returns
Return on equity	-30.5%+69.7pp	-32.6%+142pp	-35.8%+165pp	-68.7%-23.8pp	-100.1%-39.7pp
Return on assets	-28.3%+54.9pp	-21.8%+87.0pp	-21.6%+81.0pp	-58.6%-21.7pp	-83.2%-32.6pp
Return on invested capital	-38.8%+47.4pp	-104.2%+1.0pp	-99.6%+48.2pp	-68.5%-10.7pp	-86.2%-18.8pp
Liquidity
Current ratio	19.8×+14.9×	6.2×+4.7×	8.3×+7.4×	8.9×+5.3×	4.9×+1.5×
Quick ratio	19.8×+14.9×	6.2×+4.7×	8.3×+7.4×	8.9×+5.3×	4.9×+1.5×
Cash ratio	3.3×+2.8×	0.5×+0.2×	0.4×+0.3×	1.7×+0.6×	0.5×-0.6×
Leverage
Debt-to-equity	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Debt-to-assets	0×0.0×	0×0.0×	0×0.0×	0×0.0×	0×0.0×
Per Share
Book value per share	$2.67+307%	$0.77+43.7%	$0.87+366%	$1.03+20.2%	$0.66-3.5%
Valuation
Market capitalization	$1.1B+259%	$575.05M+67.3%	$549.17M+66.3%	$334.68M+194%	$216.67M+148%
Enterprise value	$1.06B+251%	$571.41M+70.0%	$547.31M+67.9%	$321.07M+222%	$212.83M+163%
Price / book	4.6×-1.6×	9.4×-1.2×	7.7×-19.0×	4.2×+1.9×	4.4×+1.8×
Free cash flow yield	-3.2%—	-5.7%—	——	——	——
Earnings yield	-4%+9.5pp	-2.7%+15.5pp	-2.7%+14.5pp	-13.5%+6.4pp	-19.1%+9.4pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Corvus Pharmaceuticals's ratios come from?: Every ratio is computed from Corvus Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.